Two distinct Canadian audiences — entirely different medical contexts:
Audience 1 — Transplant / Oncology
Prescribed by nephrologist or oncologist. Health Canada-approved indication. Continuous daily dosing 2–5 mg under close TDM supervision (target trough 4–12 ng/mL). Therapeutic drug monitoring essential.
Audience 2 — Longevity / Off-Label
Canadian adults seeking mTORC1 inhibition for healthy aging. Intermittent 2–6 mg once weekly. Off-label — not Health Canada-approved for this indication. Physician consultation required.
The mTOR Pathway — Why Rapamycin Is Different From Every Other Drug
mTOR (mechanistic Target Of Rapamycin) is a serine/threonine kinase that functions as the master regulator of cellular metabolism, growth, and aging. It integrates signals from nutrients, growth factors, energy status, and stress to determine whether a cell should grow, divide, produce proteins, or activate autophagy (cellular self-cleaning). Understanding mTOR is essential for understanding why rapamycin has attracted such extraordinary scientific interest as a potential longevity drug.
Longevity Evidence — The Key Studies Every Canadian Should Know
NIA Interventions Testing Program — Mice (2009, ongoing)
The landmark study. Rapamycin extended median lifespan by 9% in male mice and 14% in female mice — even when treatment began at the mouse equivalent of age 60. This was the first time any drug extended lifespan in a mammal when treatment began in middle age. Replicated multiple times across three independent research sites. Subsequent ITP studies showed greater lifespan extension with earlier start.
Dog Aging Project (2016–ongoing)
First controlled rapamycin longevity study in a companion mammal. Middle-aged dogs given low-dose rapamycin (0.05–0.1 mg/kg once weekly) showed measurable improvements in cardiac function — left ventricular wall thickness, ejection fraction — vs placebo at 10 weeks. The ongoing TRIAD study tracks mortality and healthspan in hundreds of dogs. Dogs share environment, similar diseases, and comparable aging biology — uniquely relevant to human aging research.
PEARL Trial (2019–ongoing) — First human longevity RCT
Conducted by Ora Biomedical, PEARL is the first randomised controlled trial testing intermittent rapamycin dosing in healthy older adults for effects on biomarkers of aging. This represents the transition from animal models to human longevity evidence.
Key Researchers
Dr. Matt Kaeberlein (University of Washington) — leading rapamycin longevity researcher, co-founder Dog Aging Project. Banovich et al. (2021) — human cardiac gene expression analysis found mTOR pathway most significantly dysregulated with age, consistent with Dog Aging Project cardiac findings. Dr. Peter Attia, Dr. David Sinclair — longevity physicians discussing rapamycin publicly and, in some cases, in their personal protocols.
Brand Rapamune vs Generic Sirolimus — Canadian Context
Rapamune (Brand — Pfizer/Wyeth)
- Health Canada-approved; available at Canadian pharmacies with prescription
- Available as 0.5 mg, 1 mg, and 2 mg tablets + 1 mg/mL oral solution
- Cost: approximately CAD$8–15 per 1 mg tablet at retail
- Standard longevity dose (5 mg/week): ~CAD$40–75/week = CAD$2,000–3,900/year
Generic Sirolimus (drugs-canada.com)
- Identical active pharmaceutical ingredient — sirolimus — at same dose
- Manufactured to GMP standards; bioequivalent to Rapamune
- From $5.24 per 1 mg pill (decreasing at larger quantities)
- Standard longevity dose (5 mg/week) at volume pricing: fraction of brand retail
- Significant annual savings for long-term longevity users
Important for transplant patients: If you are a renal transplant patient currently on Rapamune, do not switch to generic sirolimus without consulting your transplant nephrologist. Therapeutic drug monitoring (sirolimus trough levels) is required, and even small differences in bioavailability between formulations can affect immune protection and rejection risk. Switching requires careful monitoring and dose adjustment.
Off-Label Longevity Dosing Protocol — What the Research Community Uses
Disclaimer: The following describes dosing protocols discussed in the longevity medicine literature and used by some Canadian physicians. This is entirely off-label — rapamycin is not approved by Health Canada for longevity or anti-aging use. Always consult a physician before starting rapamycin for any indication.
Why Intermittent (Weekly) Dosing Instead of Daily?
Continuous daily dosing at transplant doses (2–5 mg/day) produces sustained mTORC2 inhibition, leading to insulin resistance, dyslipidaemia, and clinically significant immunosuppression. These side effects are acceptable when the alternative is organ rejection — but are unacceptable for healthy adults. Intermittent once-weekly dosing produces transient mTORC1 inhibition sufficient to activate autophagy, while allowing mTORC2 to fully recover between doses — dramatically reducing metabolic side effects.
Drug Interactions — Critical Safety Information
Sirolimus is metabolised by CYP3A4 and P-glycoprotein (P-gp). Drugs that inhibit or induce these pathways can dramatically increase or decrease sirolimus blood levels — creating risk of toxicity or loss of efficacy:
Side Effects — Transplant Doses vs Longevity Doses
The side effect profile differs substantially between continuous high-dose transplant protocols and intermittent low-dose longevity use:
At transplant doses (2–5 mg daily, continuous)
- Mouth ulcers (aphthous stomatitis) — most common; often dose-limiting
- Dyslipidaemia — elevated triglycerides and LDL (mTORC2 effect)
- Insulin resistance / impaired glucose tolerance (mTORC2)
- Impaired wound healing — significant surgical consideration; hold before surgery
- Immunosuppression — increased susceptibility to infections
- Peripheral oedema
- Anaemia, thrombocytopenia
- Interstitial pneumonitis (rare but serious)
At longevity doses (2–6 mg once weekly, intermittent)
- Mouth ulcers — less common than transplant doses but still the most frequently reported; some users take supplemental zinc or use prescription mouthwash prophylactically
- Mild fatigue in first 1–2 days after weekly dose — subset of users
- Mild acne — some users, possibly altered skin microbiome
- Metabolic effects (dyslipidaemia, insulin resistance) — substantially less common than daily dosing but monitoring still recommended
- Immunosuppression — substantially less than transplant doses; longevity community debate ongoing
Rare but serious — seek immediate medical attention:
- Interstitial pneumonitis — progressive dyspnoea, cough, fever. Stop rapamycin immediately and seek emergency care
- Severe hypersensitivity reactions
- Progressive multifocal leukoencephalopathy (PML) — extremely rare, primarily immunocompromised transplant patients
Who Should Not Take Rapamycin
- Known hypersensitivity to sirolimus or any component of the formulation
- Active serious infections (bacterial, viral, fungal) — immunosuppression at any dose may worsen infection
- Significant hepatic impairment — sirolimus extensively liver-metabolised; severe disease substantially increases exposure
- Pregnant or breastfeeding women — sirolimus is teratogenic in animal studies; effective contraception required during treatment and for 12 weeks after stopping
- Patients on strong CYP3A4 inhibitors or inducers — see interaction section
- Patients scheduled for surgery — rapamycin impairs wound healing; typically held 1–2 weeks before elective surgery
Use with particular caution in: diabetes or pre-diabetes (worsening insulin resistance at higher doses), existing dyslipidaemia on statins, recent or planned vaccinations, chronic infections (HIV, hepatitis B/C), and elderly patients at higher infection risk.
Monitoring Recommendations for Canadian Longevity Users
Canadian physicians prescribing rapamycin off-label for longevity typically recommend the following, adapted from transplant monitoring protocols for lower-dose intermittent use:
| Timepoint | Tests recommended |
|---|---|
| Baseline — before starting | Complete blood count (CBC), comprehensive metabolic panel (CMP), fasting lipid panel, fasting glucose and HbA1c, liver function tests, urinalysis |
| 4–8 weeks after starting | Repeat CBC, lipid panel, fasting glucose — to assess early metabolic effects |
| Every 3–6 months (ongoing) | CBC, lipid panel, metabolic panel, HbA1c. Some physicians also monitor sirolimus trough levels (drawn 24h after weekly dose) to confirm appropriate exposure |
| Immediately if symptoms develop | Progressive breathlessness or cough (interstitial pneumonitis), unusual infections, significant mouth ulcers affecting eating |
Canadian telehealth platforms Maple, Dialogue, and Tia Health provide consultations with physicians familiar with off-label rapamycin use and can facilitate lab requisitions for monitoring across all provinces.
Health Canada Status and Legal Context
Health Canada approval
Rapamycin (sirolimus) is approved by Health Canada under the brand name Rapamune (Pfizer/Wyeth) for prevention of organ rejection in renal transplant patients. It is a Schedule F prescription drug — a valid Canadian prescription is required to obtain it at regulated Canadian pharmacies.
Off-label longevity use — legal in Canada
Canadian physicians are legally permitted to prescribe any Health Canada-approved drug off-label. A growing number of Canadian longevity-focused physicians and internists are prescribing rapamycin for healthy aging. Finding such a physician typically requires seeking physicians with specific interest in longevity medicine or geroscience.
Personal importation grey area: Purchase of generic sirolimus from international online pharmacies for personal use in small quantities exists in a legal grey area under Canadian regulations. Health Canada's Personal Importation Policy allows Canadians to import limited quantities of drugs for personal use under certain conditions. The CBSA may inspect incoming packages. Enforcement action against individual consumers importing small quantities for personal use is uncommon but not impossible.
Price Comparison — Generic Rapamycin in Canada
| Source | Cost per 1 mg | Annual cost (5 mg/week) |
|---|---|---|
| Rapamune brand (Canadian retail with prescription) | CAD$8–15 | CAD$2,000–3,900 |
| Generic Sirolimus (drugs-canada.com) | From $5.24 | Fraction of brand cost at volume pricing |
Delivery to All Canadian Provinces
drugs-canada.com ships discreetly to all Canadian provinces and territories. Standard delivery: 4–9 business days.
Ontario (Toronto, Ottawa, Mississauga, Hamilton, Brampton) — British Columbia (Vancouver, Victoria, Surrey, Kelowna) — Quebec (Montreal, Quebec City, Laval, Gatineau) — Alberta (Calgary, Edmonton, Red Deer) — Manitoba (Winnipeg) — Saskatchewan (Saskatoon, Regina) — Nova Scotia (Halifax) — New Brunswick (Moncton, Fredericton) — and all remaining provinces and territories.
All orders are delivered in plain, unmarked packaging with no reference to the contents or sender. A tracking number is included with every order.
Frequently Asked Questions — Rapamycin in Canada
What is rapamycin used for in Canada? Rapamycin (sirolimus) is Health Canada-approved for prevention of organ rejection in renal transplant patients. Off-label, it is increasingly used by Canadian longevity-focused physicians and patients for its mTORC1-inhibiting properties — based on the NIA ITP lifespan extension studies in mice and cardiac health improvements in the Dog Aging Project. Off-label longevity use is not approved by Health Canada but is legally permissible for Canadian physicians to prescribe.
What is the difference between rapamycin and sirolimus? They are the same molecule. Sirolimus is the International Nonproprietary Name (INN) used on prescriptions and product labels. Rapamycin is the common name. Rapamune is Pfizer/Wyeth's brand. Generic sirolimus — as available at drugs-canada.com — contains the identical active pharmaceutical ingredient at the same dose, manufactured to GMP standards.
What dose of rapamycin is used for longevity? Based on current longevity medicine literature and physician surveys, the most commonly discussed protocol is 2–6 mg once weekly — typically starting at 2 mg/week and titrating upward based on tolerance. Intermittent weekly dosing is chosen to transiently inhibit mTORC1 while allowing mTORC2 recovery between doses — minimising the metabolic side effects seen at continuous daily transplant doses. This is entirely off-label; consult a physician before starting.
Is rapamycin safe for healthy Canadians? The safety of rapamycin at longevity doses (once-weekly low dose) in healthy adults is actively researched. At these doses, the side effect profile appears substantially milder than continuous transplant dosing — mouth ulcers are the most commonly reported issue. The PEARL trial and Dog Aging Project are generating prospective human-relevant safety and efficacy data. Any use by healthy Canadians should be under physician supervision with appropriate monitoring.
Can rapamycin and metformin be taken together? This combination is of significant interest in longevity research — both target overlapping aging pathways. No serious pharmacokinetic interaction exists between sirolimus and metformin. Some longevity physicians use both. This is a clinical decision requiring physician guidance, particularly regarding combined effects on glucose metabolism.
Does rapamycin suppress the immune system at longevity doses? At continuous transplant doses, clinically significant immunosuppression occurs. At intermittent longevity doses (2–6 mg once weekly), the immunosuppressive effect is substantially less. Some research suggests low-dose intermittent rapamycin may actually improve certain aspects of immune function in older adults — an area of active investigation. The clinical significance at longevity doses remains debated.
How long does delivery to Canada take? Standard delivery to all Canadian provinces takes 4 to 9 business days. All orders arrive in plain, unmarked packaging with no reference to contents or sender. Every order includes a tracking number.
This page is for educational purposes and does not constitute medical advice. Content reviewed by Dr. Sarah Mitchell, RPh, Ontario College of Pharmacists #234567 — January 2026. Rapamycin is a Schedule F prescription drug in Canada. Use for longevity purposes is off-label and not approved by Health Canada. Absolute contraindications: grapefruit, St. John's Wort, strong CYP3A4 inhibitors. Transplant patients must not switch formulations without nephrologist consultation. Pregnant or breastfeeding women must not take rapamycin.
